Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Eberswalde – page 39

1 792 clinical trials in Eberswalde, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Eberswalde at a glance
1 792
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 792 trials in Eberswalde

Open in trial search

Study on the Effectiveness of E. coli DSM 17252 for Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:SymbioPharm GmbH

Study on the Safety and Effectiveness of Tafasitamab for Children with Relapsed or Refractory Acute B Lineage Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Tafasitamab
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Study on High-Dose Chemotherapy with Cytarabine and Drug Combination for Elderly Patients with Primary CNS Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:65+ years
  • Substances:Busulfan
  • Sponsor:Medical Center - University Of Freiburg

Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Daiichi Sankyo Inc.

Cystic fibrosis

Recruiting

Study on the Safety and Effects of SPL84 for Patients with Cystic Fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:SPL84-23-1
  • Sponsor:Splisense Ltd.

Study on the Effectiveness and Safety of Plixorafenib (FORE8394) for Patients with Cancer Having BRAF Alterations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cobicistat
  • Sponsor:Fore Biotherapeutics Inc.

Study on Acalabrutinib, Obinutuzumab, and Venetoclax for Untreated High-Risk Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:University Of Cologne

Study on Letrozole Maintenance Therapy for Patients with Epithelial Ovarian Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Swiss GO Trial Group

Study on Crofelemer for Adults with Short Bowel Syndrome and Intestinal Failure Without Colon in Continuity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Crofelemer
  • Sponsor:Napo Therapeutics S.p.A.

Neoplasm malignant+1

Recruiting

Study on the Safety of Encorafenib, Binimetinib, and Ribociclib for Patients with Solid Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Pfizer Inc.

Neoplasm

Recruiting

Study on Treating Solid Tumors with Genetically Modified T-Cells (IMA203, IMA203CD8) and Nivolumab for Patients with Recurrent or Refractory Conditions

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:IMA203CD8
  • Sponsor:Immatics US Inc.

Study on the Effects of Cyclosporine A in Patients with Takotsubo Syndrome

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ciclosporin
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Eberswalde

What the registry says about research in the country

01 Hematologic Oncology

Clinical research focusing on Diffuse Large B-Cell Lymphoma (DLBCL) and its various subtypes, evaluating innovative combination therapies for elderly patients.

  • Treatment optimization for older adults
  • B-cell lymphoma variants
  • Targeted therapy combinations

The study explores the effectiveness of combining acalabrutinib with standard lymphoma treatments to improve outcomes in patients over 60 and 80 years of age.

02 Specialized Lymphoma Research

Investigation of multiple B-cell lymphoma subtypes, including rare variants such as primary cutaneous, intravascular, and mediastinal forms.

  • Novel therapeutic approaches
  • Rare lymphoma variants
  • Treatment response assessment

Research aims to enhance progression-free survival through targeted therapeutic strategies.

03 Personalized Medicine

Advancing treatment protocols for elderly lymphoma patients with focus on reduced-intensity therapy combinations.

  • Age-adapted treatments
  • Quality of life considerations
  • Therapeutic efficacy

Studies evaluate modified treatment regimens designed specifically for older adults who cannot tolerate standard intensive therapies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.